After enjoying a strong run from the fall of 2020 through to the spring of this year, AngioDynamics (ANGO) shares have flattened out. I would attribute at least some of this to a more cautious market towards smaller med-tech, but also some level of “wait and see” on the part of investors regarding management’s ability to drive a sustained improvement in the business on the back of its thrombectomy, atherectomy, and oncology electroporation technologies.
AngioDynamics’ spotty execution history and higher investor expectations were significant factors in my neutral stance on AngioDynamics back in April, and the shares haven’t done much since then. I liked the better-than-expected fiscal fourth quarter results and the improved guidance for fiscal 2022, and I still see a path to a fair value close to $30, but this remains a riskier-than-average execution-driven story with not all that much following on the Street.
Read more here:
AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration
No comments:
Post a Comment